Literature DB >> 17918017

Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia.

Michelle R Ananda-Rajah1, Patrick G P Charles, Sharmila Melvani, Laurelle L Burrell, Paul D R Johnson, M Lindsay Grayson.   

Abstract

Pneumonia severity assessment systems such as the pneumonia severity index (PSI) and CURB-65 were designed to direct appropriate site of care based on 30-d mortality. Increasingly they are being used to guide empirical antibiotic therapy and also possibly to detect patients who will require admission to the intensive care unit (ICU). We retrospectively reviewed the records of all patients admitted to our institution with confirmed community acquired pneumonia (CAP) for the 12 months from January 2002. 408 episodes were studied with an overall 30-d mortality of 15.4% and ICU admission of 10.5%. PSI classes IV/V were significantly better than CURB-65 score > or = 3 for predicting patients who died within 30 d (94% vs 62%; p < 0.001), and those that needed ICU (86% vs 61%; p = 0.01). In addition, for the patients identified as 'low risk' by PSI (classes I/II), there was only 1 death and 1 admission to an ICU compared to 8 deaths and 7 ICU admissions with CURB-65 scores of 0-1. Although easier to use, CURB-65 is neither sensitive nor specific for predicting mortality in CAP patients. Neither rule was sufficiently accurate for predicting need for an ICU, even when patients with 'not for resuscitation' orders were excluded.

Entities:  

Mesh:

Year:  2008        PMID: 17918017     DOI: 10.1080/00365540701663381

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  16 in total

1.  CURB-65 pneumonia severity assessment adapted for electronic decision support.

Authors:  Barbara E Jones; Jason Jones; Thomas Bewick; Wei Shen Lim; Dominik Aronsky; Samuel M Brown; Wim G Boersma; Menno M van der Eerden; Nathan C Dean
Journal:  Chest       Date:  2010-12-16       Impact factor: 9.410

2.  Severe Pneumonia Treated Succesfully with Levofloxacin and Oseltamivir During Flu Epidemic.

Authors:  Pınar Akın Kabalak; Asım Esenkaya
Journal:  Turk Thorac J       Date:  2016-04-01

3.  Audit and Feedback-Focused approach to Evidence-based Care in Treating patients with pneumonia in hospital (AFFECT Study).

Authors:  Katelyn Halpape; Linda Sulz; Brenda Schuster; Ron Taylor
Journal:  Can J Hosp Pharm       Date:  2014-01

Review 4.  Defining severe pneumonia.

Authors:  Samuel M Brown; Nathan C Dean
Journal:  Clin Chest Med       Date:  2011-07-12       Impact factor: 2.878

Review 5.  Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis.

Authors:  James D Chalmers; Pallavi Mandal; Aran Singanayagam; Ahsan R Akram; Gourab Choudhury; Philip M Short; Adam T Hill
Journal:  Intensive Care Med       Date:  2011-06-10       Impact factor: 17.440

Review 6.  Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality.

Authors:  T Welte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

7.  Mortality Risk and Etiologic Spectrum of Community-acquired Pneumonia in Hospitalized Adult Patients.

Authors:  Cornelia Tudose; Adriana Moisoiu; Miron Bogdan
Journal:  Maedica (Buchar)       Date:  2010-12

Review 8.  Defining and predicting severe community-acquired pneumonia.

Authors:  Samuel M Brown; Nathan C Dean
Journal:  Curr Opin Infect Dis       Date:  2010-04       Impact factor: 4.915

9.  Comparison of severity of illness scoring systems in the prediction of hospital mortality in severe sepsis and septic shock.

Authors:  Colleen A Crowe; Erik B Kulstad; Chintan D Mistry; Christine E Kulstad
Journal:  J Emerg Trauma Shock       Date:  2010-10

10.  Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; Navneet Singh; Narayan Mishra; G C Khilnani; J K Samaria; S N Gaur; S K Jindal
Journal:  Lung India       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.